 HAMPTON, N.J., July 16, 2021 GLOBE NEWSWIRE -- Celldex Therapeutics, Inc. Celldex or the Company Nasdaq: CLDX today announced the closing of its previously announced underwritten public offering of 6,845,238 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 892,857 shares, at a public offering price of 42.00 per share. The gross proceeds to Celldex from this offering were approximately 287.5 million, before deducting underwriting discounts and commissions and offering expenses. 